The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
July 11th 2025, 9:08pm
Paolo Tarantino, MD, details the role of ADCs in HER2-positive breast cancer, along with unmet needs that persist.
July 11th 2025, 7:31pm
Heather McArthur, MD, MPH, FASCO, discusses the efficacy of pembrolizumab/chemo and sequencing the regimen in early triple-negative breast cancer.
July 7th 2025, 8:34pm
ESMO Gastrointestinal Cancers Congress
Panitumumab plus FOLFIRINOX or mFOLFOX6 did not elicit meaningful responses in previously untreated, liver-limited, RAS/BRAF wild-type unresectable mCRC.
July 7th 2025, 8:15pm
ESMO Gastrointestinal Cancers Congress
Ivosidenib was effective for the real-world treatment of patients with IDH1-mutated cholangiocarcinoma.
July 7th 2025, 4:44pm
ESMO Gastrointestinal Cancers Congress
A real-world analysis showed that patients with KRAS G12C–mutant mCRC had shorter OS and PFS after first-line treatment vs those with non-G12C mutations.
July 7th 2025, 4:26pm
ESMO Gastrointestinal Cancers Congress
Efficacy results from a MAIC suggest potential benefit with nivolumab/ipilimumab over other first-line IO-based regimens in first-line unresectable HCC.
July 6th 2025, 6:06pm
ESMO Gastrointestinal Cancers Congress
IRIGA trial comparing mFOLFIRINOX vs mFOLFOX6 shows mixed results in HER2-negative metastatic gastric and GEJ adenocarcinoma.
July 5th 2025, 8:45pm
ESMO Gastrointestinal Cancers Congress
Tislelizumab plus chemotherapy improves efficacy vs chemotherapy alone in locally advanced ESCC, including those with PD-L1 TAP of 5% or higher.
July 5th 2025, 5:55pm
ESMO Gastrointestinal Cancers Congress
Treatment with trifluridine/tipiracil led to an improvement in disease-free survival in ctDNA-positive colorectal cancer after curative resection.
July 5th 2025, 5:29pm
ESMO Gastrointestinal Cancers Congress
ctDNA monitoring led to earlier recurrence detection and increased use of curative-intent treatment after recurrence in nonmetastatic colorectal cancer.
July 5th 2025, 9:00am
ESMO Gastrointestinal Cancers Congress
Richard Finn, MD, discusses the addition of tiragolumab to atezolizumab and bevacizumab in advanced hepatocellular carcinoma.
July 5th 2025, 8:48am
ESMO Gastrointestinal Cancers Congress
Rocío García-Carbonero, MD, discusses a subgroup analysis of fruquintinib vs placebo in patients with refractory metastatic colorectal cancer.
July 4th 2025, 6:46pm
ESMO Gastrointestinal Cancers Congress
A real-world study in Portugal showed fruquintinib displayed a manageable safety profile and an efficacy trend in refractory colorectal cancer.
July 4th 2025, 6:19pm
ESMO Gastrointestinal Cancers Congress
Nivolumab plus ipilimumab maintained an ORR benefit across subgroups of Chinese patients with unresectable hepatocellular carcinoma.
July 4th 2025, 5:28pm
ESMO Gastrointestinal Cancers Congress
Quantitative vessel tortuosity features were able to detect the VEGFR inhibitory mechanism of fruquintinib in metastatic colorectal cancer.
July 4th 2025, 4:38pm
ESMO Gastrointestinal Cancers Congress
A survey of UK and German physicians found that OS gains were needed to accept increased toxicities or treatment burden with third-line regimens in mCRC.
July 4th 2025, 1:43pm
ESMO Gastrointestinal Cancers Congress
Benjamin L. Schlechter, MD, discusses efficayc and safety of botensilimab in combination with the anti–PD-1 antibody balstilimab in mCRC.
July 4th 2025, 1:30pm
ESMO Gastrointestinal Cancers Congress
Post hoc analyses compared encorafenib plus cetuximab and mFOLFOX6 with different BREAKWATER control arm regimens.
July 4th 2025, 1:30pm
ESMO Gastrointestinal Cancers Congress
A post hoc subgroup analysis of FRESCO-2 shed light on the safety and efficacy of fruquintinib by metastatic site in metastatic colorectal cancer.
July 4th 2025, 10:34am
ESMO Gastrointestinal Cancers Congress
Yelena Y. Janjigian, MD, discusses patient-reported outcomes and QOL assessments for durvalumab plus FLOT in resectable gastric/GEJ adenocarcinoma.